Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Lumos Diagnostics Holdings Ltd. ( (AU:LDX) ) is now available.
Lumos Diagnostics has secured a A$5.0 million loan facility with major shareholders Tenmile Ventures and Ryder Capital, providing financial flexibility as it seeks a CLIA waiver from the U.S. FDA for its FebriDx® test. This agreement replaces a previous convertible note arrangement and aims to support the company’s strategic goals while minimizing equity dilution, highlighting the ongoing commitment of its shareholders.
More about Lumos Diagnostics Holdings Ltd.
Lumos Diagnostics is a leader in rapid, point-of-care diagnostic technologies, specializing in complete diagnostic test technology to aid healthcare professionals in diagnosing and managing medical conditions. The company offers customized assay development, manufacturing services for point-of-care tests, and proprietary digital reader platforms, focusing on infectious and inflammatory diseases.
Average Trading Volume: 6,745,638
Technical Sentiment Signal: Buy
Current Market Cap: A$98.89M
For detailed information about LDX stock, go to TipRanks’ Stock Analysis page.